AstraZeneca Pharmaceuticals LP
NEWS
AstraZeneca reported it plans to manufacture as much as 30 million doses of the vaccine for the U.K. market by September, with expectations of 100 million doses by the end of the year.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
The Lynparza approval isn’t as broad as the Zejula approval, with Lynparza not approved for use in patients with homologous recombination deficiencies.
The drug can potentially reduce the risk of cardiovascular death and hospitalization for heart failure.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
AstraZeneca and the University of Oxford have partnered on the global development and distribution of Oxford’s COVID-19 vaccine it is developing.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
AstraZeneca and Merck & Co. released more positive data from the Phase III PROfound trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer.
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
JOBS
IN THE PRESS